Posted by Michael Wonder on 06 Mar 2021
U.S. FDA approves Yescarta for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
5 March 2021 - Yescarta is the first CAR T-cell therapy approved for indolent follicular lymphoma; approval marks the third indication for a Kite cell therapy.
Kite today announced that the U.S. FDA has granted accelerated approval to Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The approval makes Yescarta the first chimeric antigen receptor T-cell therapy approved for patients with indolent follicular lymphoma, follows FDA breakthrough therapy designation and a priority review, and marks the third approved indication for a Kite cell therapy.
